The Kent & Medway ICB continue to develop pathways to provide a fair approach for patients wanting to access Mounjaro, starting with those at greatest clinical need.
Though it has been announced that Mounjaro is now available from GPs (for a specific patient cohort), NICE guidelines state in order to gain access to Mounjaro on the NHS, patients MUST also be referred to a diet and exercise support programme.
Arrangements are still being made to mobilise a provider of the necessary support programme.
Until this service is in place, it is NOT possible for the GP to prescribe Mounjaro for weight loss.
Please follow this link for more information, and answers to frequently asked questions relating to Mounjaro.
Update on availability of Wegovy (semaglutide) and Mounjaro (tirzepatide) to support weight loss :: Kent & Medway ICS
Your general practice or hospital services will not be able to prescribe this medication to you for Obesity until arrangements are in place.
Please do not contact your GP or hospital service for medication for weight management as they have been asked not to prescribe it at this time.
Accessing Wegovy for weight loss
Wegovy is the brand name for semaglutide, a drug which has been licensed and approved by the National Institute for Health and Care Excellence (NICE) for the management of obesity.
Work is now being carried out with specialists across Kent and Medway to allow appropriate referrals to take place.
As arrangements and supply are still being confirmed, we are not currently able to process any referrals to local specialist services for the consideration of prescribing Wegovy.
Wegovy will only be supplied through specialist services. This is to make sure that correct support such as diet and nutritional services are available alongside the medication.
Your GP practice will not be able to prescribe this medication to you and specialist services should not be contacted to obtain this medication until arrangements are in place.
Accessing Mounjaro for weight loss
Monjuro is the brand name for tirzepatide, a drug which has been licensed and approved by the National Institute for Health and Care Excellence (NICE) for managing overweight and obesity.
Monjuro will become available only via specialist weight management services. This is to make sure that correct support such as diet and nutritional services are available alongside the medication.
Your GP practice will not be able to prescribe this medication to you and specialist services should not be contacted to obtain this medication until arrangements are in place.
We will update this information when arrangements are in place.